Please login to the form below

Not currently logged in
Email:
Password:

RCC

This page shows the latest RCC news and features for those working in and with pharma, biotech and healthcare.

Keytruda combo outshines Opdivo in kidney cancer

Keytruda combo outshines Opdivo in kidney cancer

has landed a blow against rivals BMS and its lead in immunotherapy treatment of renal cell carcinoma (RCC). . ... The drug combinations aren’t being compared head-to-head yet, but both have been tested against current standard sunitinib for first-line

Latest news

More from news
Approximately 12 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    I think these is some really game-changing data for first-line and second-line RCC patients.”. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics